130 related articles for article (PubMed ID: 27415446)
1. Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer.
Journy NM; Morton LM; Kleinerman RA; Bekelman JE; Berrington de Gonzalez A
JAMA Oncol; 2016 Oct; 2(10):1368-1370. PubMed ID: 27415446
[No Abstract] [Full Text] [Related]
2. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.
Wang R; Zeidan AM; Yu JB; Soulos PR; Davidoff AJ; Gore SD; Huntington SF; Gross CP; Ma X
Prostate; 2017 Apr; 77(5):437-445. PubMed ID: 27868212
[TBL] [Abstract][Full Text] [Related]
3. Radiation-induced second cancers: the impact of 3D-CRT and IMRT.
Hall EJ; Wuu CS
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):83-8. PubMed ID: 12694826
[TBL] [Abstract][Full Text] [Related]
4. Why is there so much therapy-related AML and MDS and so little therapy-related CML?
Gale RP; Hlatky L; Sachs RK; Radivoyevitch T
Leuk Res; 2014 Oct; 38(10):1162-4. PubMed ID: 25175829
[No Abstract] [Full Text] [Related]
5. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
6. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
[TBL] [Abstract][Full Text] [Related]
7. Risk of second cancers according to radiation therapy technique and modality in prostate cancer survivors.
Berrington de Gonzalez A; Wong J; Kleinerman R; Kim C; Morton L; Bekelman JE
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):295-302. PubMed ID: 25636756
[TBL] [Abstract][Full Text] [Related]
8. [Therapy-related hematologic neoplasias after breast cancer. Epidemiologic, etiologic and cytogenetic aspects and new risk factors according to published data and own results].
Haase D; Hanf V; Schulz T
Med Klin (Munich); 2004 Sep; 99(9):506-17. PubMed ID: 15372180
[TBL] [Abstract][Full Text] [Related]
9. The risk of second primary cancers due to peripheral photon and neutron doses received during prostate cancer external beam radiation therapy.
Bezak E; Takam R; Yeoh E; Marcu LG
Phys Med; 2017 Oct; 42():253-258. PubMed ID: 28302493
[TBL] [Abstract][Full Text] [Related]
10. Late toxicity after conformal and intensity-modulated radiation therapy for prostate cancer: impact of previous surgery for benign prostatic hyperplasia.
Odrazka K; Dolezel M; Vanasek J; Vaculikova M; Zouhar M; Sefrova J; Paluska P; Vosmik M; Kohlova T; Kolarova I; Navratil P; Brodak M; Prosvic P; Hoffmann P
Int J Urol; 2010 Sep; 17(9):784-90. PubMed ID: 20604816
[TBL] [Abstract][Full Text] [Related]
11. The effect of intensity-modulated radiotherapy on radiation-induced second malignancies.
Ruben JD; Davis S; Evans C; Jones P; Gagliardi F; Haynes M; Hunter A
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1530-6. PubMed ID: 18207670
[TBL] [Abstract][Full Text] [Related]
12. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
13. Intensity modulated radiation therapy replaces 3-dimensional conformal radiotherapy as prostate cancer treatment.
Elliott SP; Adejoro OO; Konety BR; Jarosek SL; Dusenbery KE; Virnig BA
J Urol; 2012 Apr; 187(4):1253-8. PubMed ID: 22335868
[TBL] [Abstract][Full Text] [Related]
14. The heterogeneity of leukemia occurring after treatment for sarcoma.
Varterasian M; Zalupski M; Karanes C
Am J Clin Oncol; 1997 Dec; 20(6):585-6. PubMed ID: 9391546
[TBL] [Abstract][Full Text] [Related]
15. [Second neoplasms after percutaneous radiotherapy].
Haidl F; Pfister D; Semrau R; Heidenreich A
Urologe A; 2017 Mar; 56(3):342-350. PubMed ID: 27844130
[TBL] [Abstract][Full Text] [Related]
16. Acute non-lymphocytic leukaemia and myelofibrosis following sequential hemibody irradiation for prostatic carcinoma.
Graham P
Clin Oncol (R Coll Radiol); 1992 May; 4(3):203. PubMed ID: 1586642
[No Abstract] [Full Text] [Related]
17. Secondary leukemia: twice is a coincidence?
Akerley W
Cancer; 2000 Feb; 88(3):497-9. PubMed ID: 10649239
[No Abstract] [Full Text] [Related]
18. Health-related quality-of-life after external beam radiation therapy for localized prostate cancer: intensity-modulated radiation therapy versus conformal radiation therapy.
Yoshimura K; Kamoto T; Nakamura E; Segawa T; Kamba T; Takahashi T; Nishiyama H; Ito N; Takayama K; Mizowaki T; Mitsumori M; Hiraoka M; Ogawa O
Prostate Cancer Prostatic Dis; 2007; 10(3):288-92. PubMed ID: 17160068
[TBL] [Abstract][Full Text] [Related]
19. Incidental Dose to Pelvic Nodal Regions in Prostate-Only Radiotherapy.
Murthy V; Lewis S; Sawant M; Paul SN; Mahantshetty U; Shrivastava SK
Technol Cancer Res Treat; 2017 Apr; 16(2):211-217. PubMed ID: 27492806
[TBL] [Abstract][Full Text] [Related]
20. Risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia after childhood cancer: a population-based study.
Advani PG; Schonfeld SJ; Curtis RE; Dores GM; Linet MS; Sigel BS; Lam CJK; Tucker MA; Chanock SJ; Morton LM
Leukemia; 2019 Dec; 33(12):2947-2978. PubMed ID: 31341236
[No Abstract] [Full Text] [Related]
[Next] [New Search]
